Epidermal growth factor receptor expression analysis in chemotherapy-naive patients with advanced non-small-cell lung cancer treated with gefitinib or placebo in combination with platinum-based chemotherapy

Giuseppe Giaccone, Renee B. Iacona, Abderrahim Fandi, Mette Janas, Judith S. Ochs, Roy S. Herbst, David H. Johnson

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Purpose: Two large, randomized, placebo-controlled trials (IRESSA NSCLC Trial Assessing Combination Therapy; INTACT 1 and 2) in non-small-cell lung cancer (NSCLC) failed to show survival benefit for gefitinib (IRESSA) in combination with first-line platinum-based chemotherapy. Epidermal growth factor receptor (EGFR) staining was assessed retrospectively in relation to survival response to gefitinib in combination with chemotherapy. Methods: Tumor biopsies obtained prior to start of therapy were assessed by immunohistochemistry for EGFR using the Dako EGFR pharmDx assay™ (Dako, Denmark). Analyses were stratified by trial and performed independently for patients randomized to placebo and gefitinib as well as for both treatment groups combined. A restricted backwards elimination Cox regression analysis was conducted to identify independent EGFR factors that were statistically significant (P < 0.10), and these were also tested for treatment interaction to assess if they served as predictive factors. Results: Analyses found two statistically significant EGFR-based prognostic factors representing growth pattern and percent membrane staining in patients treated with gefitinib (P = 0.0023), placebo (P = 0.0128), and both combined (P < 0.0001). The prognostic effect was independent of other known prognostic factors. There was no predictive effect of either the growth pattern or membrane staining variable. Conclusions: While some previous studies indicate that higher EGFR expression correlates with poor survival, our analyses provide statistically significant evidence that the combination of EGFR expression and growth pattern is a strong prognostic indicator for improved survival within this setting. The effects of membrane staining and growth pattern are still significant when adjusting for mutation.

Original languageEnglish (US)
Pages (from-to)467-476
Number of pages10
JournalJournal of Cancer Research and Clinical Oncology
Volume135
Issue number3
DOIs
StatePublished - Mar 2009

Fingerprint

Platinum
Epidermal Growth Factor Receptor
Non-Small Cell Lung Carcinoma
Placebos
Drug Therapy
Staining and Labeling
Growth
Membranes
Survival
Denmark
Therapeutics
Survival Analysis
gefitinib
Combination Drug Therapy
Randomized Controlled Trials
Immunohistochemistry
Regression Analysis
Biopsy
Mutation
Neoplasms

Keywords

  • Biomarkers
  • Chemotherapy
  • EGFR
  • Gefitinib
  • Immunohistochemistry
  • NSCLC
  • Tumor biopsies

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Epidermal growth factor receptor expression analysis in chemotherapy-naive patients with advanced non-small-cell lung cancer treated with gefitinib or placebo in combination with platinum-based chemotherapy. / Giaccone, Giuseppe; Iacona, Renee B.; Fandi, Abderrahim; Janas, Mette; Ochs, Judith S.; Herbst, Roy S.; Johnson, David H.

In: Journal of Cancer Research and Clinical Oncology, Vol. 135, No. 3, 03.2009, p. 467-476.

Research output: Contribution to journalArticle

@article{fc551b00205c410087417a88cc416ff9,
title = "Epidermal growth factor receptor expression analysis in chemotherapy-naive patients with advanced non-small-cell lung cancer treated with gefitinib or placebo in combination with platinum-based chemotherapy",
abstract = "Purpose: Two large, randomized, placebo-controlled trials (IRESSA NSCLC Trial Assessing Combination Therapy; INTACT 1 and 2) in non-small-cell lung cancer (NSCLC) failed to show survival benefit for gefitinib (IRESSA) in combination with first-line platinum-based chemotherapy. Epidermal growth factor receptor (EGFR) staining was assessed retrospectively in relation to survival response to gefitinib in combination with chemotherapy. Methods: Tumor biopsies obtained prior to start of therapy were assessed by immunohistochemistry for EGFR using the Dako EGFR pharmDx assay™ (Dako, Denmark). Analyses were stratified by trial and performed independently for patients randomized to placebo and gefitinib as well as for both treatment groups combined. A restricted backwards elimination Cox regression analysis was conducted to identify independent EGFR factors that were statistically significant (P < 0.10), and these were also tested for treatment interaction to assess if they served as predictive factors. Results: Analyses found two statistically significant EGFR-based prognostic factors representing growth pattern and percent membrane staining in patients treated with gefitinib (P = 0.0023), placebo (P = 0.0128), and both combined (P < 0.0001). The prognostic effect was independent of other known prognostic factors. There was no predictive effect of either the growth pattern or membrane staining variable. Conclusions: While some previous studies indicate that higher EGFR expression correlates with poor survival, our analyses provide statistically significant evidence that the combination of EGFR expression and growth pattern is a strong prognostic indicator for improved survival within this setting. The effects of membrane staining and growth pattern are still significant when adjusting for mutation.",
keywords = "Biomarkers, Chemotherapy, EGFR, Gefitinib, Immunohistochemistry, NSCLC, Tumor biopsies",
author = "Giuseppe Giaccone and Iacona, {Renee B.} and Abderrahim Fandi and Mette Janas and Ochs, {Judith S.} and Herbst, {Roy S.} and Johnson, {David H.}",
year = "2009",
month = "3",
doi = "10.1007/s00432-008-0466-3",
language = "English (US)",
volume = "135",
pages = "467--476",
journal = "Journal of Cancer Research and Clinical Oncology",
issn = "0171-5216",
publisher = "Springer Verlag",
number = "3",

}

TY - JOUR

T1 - Epidermal growth factor receptor expression analysis in chemotherapy-naive patients with advanced non-small-cell lung cancer treated with gefitinib or placebo in combination with platinum-based chemotherapy

AU - Giaccone, Giuseppe

AU - Iacona, Renee B.

AU - Fandi, Abderrahim

AU - Janas, Mette

AU - Ochs, Judith S.

AU - Herbst, Roy S.

AU - Johnson, David H.

PY - 2009/3

Y1 - 2009/3

N2 - Purpose: Two large, randomized, placebo-controlled trials (IRESSA NSCLC Trial Assessing Combination Therapy; INTACT 1 and 2) in non-small-cell lung cancer (NSCLC) failed to show survival benefit for gefitinib (IRESSA) in combination with first-line platinum-based chemotherapy. Epidermal growth factor receptor (EGFR) staining was assessed retrospectively in relation to survival response to gefitinib in combination with chemotherapy. Methods: Tumor biopsies obtained prior to start of therapy were assessed by immunohistochemistry for EGFR using the Dako EGFR pharmDx assay™ (Dako, Denmark). Analyses were stratified by trial and performed independently for patients randomized to placebo and gefitinib as well as for both treatment groups combined. A restricted backwards elimination Cox regression analysis was conducted to identify independent EGFR factors that were statistically significant (P < 0.10), and these were also tested for treatment interaction to assess if they served as predictive factors. Results: Analyses found two statistically significant EGFR-based prognostic factors representing growth pattern and percent membrane staining in patients treated with gefitinib (P = 0.0023), placebo (P = 0.0128), and both combined (P < 0.0001). The prognostic effect was independent of other known prognostic factors. There was no predictive effect of either the growth pattern or membrane staining variable. Conclusions: While some previous studies indicate that higher EGFR expression correlates with poor survival, our analyses provide statistically significant evidence that the combination of EGFR expression and growth pattern is a strong prognostic indicator for improved survival within this setting. The effects of membrane staining and growth pattern are still significant when adjusting for mutation.

AB - Purpose: Two large, randomized, placebo-controlled trials (IRESSA NSCLC Trial Assessing Combination Therapy; INTACT 1 and 2) in non-small-cell lung cancer (NSCLC) failed to show survival benefit for gefitinib (IRESSA) in combination with first-line platinum-based chemotherapy. Epidermal growth factor receptor (EGFR) staining was assessed retrospectively in relation to survival response to gefitinib in combination with chemotherapy. Methods: Tumor biopsies obtained prior to start of therapy were assessed by immunohistochemistry for EGFR using the Dako EGFR pharmDx assay™ (Dako, Denmark). Analyses were stratified by trial and performed independently for patients randomized to placebo and gefitinib as well as for both treatment groups combined. A restricted backwards elimination Cox regression analysis was conducted to identify independent EGFR factors that were statistically significant (P < 0.10), and these were also tested for treatment interaction to assess if they served as predictive factors. Results: Analyses found two statistically significant EGFR-based prognostic factors representing growth pattern and percent membrane staining in patients treated with gefitinib (P = 0.0023), placebo (P = 0.0128), and both combined (P < 0.0001). The prognostic effect was independent of other known prognostic factors. There was no predictive effect of either the growth pattern or membrane staining variable. Conclusions: While some previous studies indicate that higher EGFR expression correlates with poor survival, our analyses provide statistically significant evidence that the combination of EGFR expression and growth pattern is a strong prognostic indicator for improved survival within this setting. The effects of membrane staining and growth pattern are still significant when adjusting for mutation.

KW - Biomarkers

KW - Chemotherapy

KW - EGFR

KW - Gefitinib

KW - Immunohistochemistry

KW - NSCLC

KW - Tumor biopsies

UR - http://www.scopus.com/inward/record.url?scp=59449110169&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=59449110169&partnerID=8YFLogxK

U2 - 10.1007/s00432-008-0466-3

DO - 10.1007/s00432-008-0466-3

M3 - Article

C2 - 18787840

AN - SCOPUS:59449110169

VL - 135

SP - 467

EP - 476

JO - Journal of Cancer Research and Clinical Oncology

JF - Journal of Cancer Research and Clinical Oncology

SN - 0171-5216

IS - 3

ER -